MedTrace Logo

Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer

NCT00125359 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2019-01-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to learn about the effects of two new anticancer drugs, erlotinib (Tarceva) and bexarotene (Targretin), when treating patients with advanced lung cancer.

Erlotinib is approved by the Food and Drug Administration (FDA) for the treatment of non-small-cell lung cancer (NSCLC). Bexarotene is approved by the FDA for the treatment of cutaneous T-cell lymphoma. This combination of drugs is experimental.

Conditions

  • Carcinoma, Non-small-cell Lung

Interventions

DRUG

erlotinib and bexarotene

Daily Erlotinib 150mg and daily bexarotene oral capsules 400mg.

Sponsors & Collaborators

  • Ligand Pharmaceuticals

    collaborator INDUSTRY

  • Genentech, Inc.

    collaborator INDUSTRY

  • Konstantin Dragnev

    lead OTHER

Principal Investigators

  • Konstantin H Dragnev, MD · Norris Cotton Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00125359 on ClinicalTrials.gov